Experience of linear accelerator quality assurance based on the Radiation Therapy Oncology Group specification

陆赛全; 王佳舟; 彭佳元

doi:10.19401/j.cnki.1007-3639.2018.04.011

您当前的位置：

首页 >

文章列表页 >

Experience of linear accelerator quality assurance based on the Radiation Therapy Oncology Group specification

更新时间：2026-01-27

- Experience of linear accelerator quality assurance based on the Radiation Therapy Oncology Group specification
- China Oncology Vol. 28, Issue 4, Pages: 308-314(2018)
- 作者机构：
  
  复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.04.011
  CLC： R730.55
- Published Online：12 June 2018，
  
  Published：12 June 2018
- 稿件说明：
移动端阅览
陆赛全,王佳舟,彭佳元,等. 放射治疗肿瘤协作组规范下的加速器质量保证经验[J]. 中国癌症杂志, 2018, 28(4): 308-314.

陆赛全, 王佳舟, 彭佳元. Experience of linear accelerator quality assurance based on the Radiation Therapy Oncology Group specification[J]. China Oncology, 2018, 28(4): 308-314.
陆赛全,王佳舟,彭佳元,等. 放射治疗肿瘤协作组规范下的加速器质量保证经验[J]. 中国癌症杂志, 2018, 28(4): 308-314. DOI： 10.19401/j.cnki.1007-3639.2018.04.011.

陆赛全, 王佳舟, 彭佳元. Experience of linear accelerator quality assurance based on the Radiation Therapy Oncology Group specification[J]. China Oncology, 2018, 28(4): 308-314. DOI： 10.19401/j.cnki.1007-3639.2018.04.011.

摘要

背景与目的：放射治疗的质量保证在精准实施肿瘤放射治疗中起着关键作用。本研究旨在探讨加入放射治疗肿瘤协作组（Radiation Therapy Oncology Group，RTOG）成员达到放射治疗质量保证标准的经验。方法：加入RTOG的前期准备是制定本单位加速器设备质量保证方案，包括表格和质控报告。质控项目如日检、月检、年检项目需参照美国物理学家协会（American Association of Physicists in Medicine，AAPM)TG40和AAPM TG142报告所描述的内容进行实施。实施中由一位资深物理师全权负责1~2台加速器。日检由物理师在早晨实施，月检和年检由物理师周末安排实施。日检、月检和年检的结果以电子表格存档。结果：制定并严格执行规范化的设备质量保证方案。放射治疗质量保证结果的文档数字化能直接客观地显示加速器质控情况和存在问题。结论：制定加速器质控方案并执行规范化的放疗质控规范在临床上值得推广。

Abstract

Background and purpose: The quality assurance (QA) of radiation therapy plays an important role in the precise tumor radiotherapy. This study was to report the accelerator QA experience of joining the Radiation Therapy Oncology Group (RTOG). Methods: The QA protocols and the report forms were customized by following the RTOG requirements. The daily

monthly and annual quality assurance items were created according to the American Association of Physicists in Medicine (AAPM) TG40 and AAPM TG142. Each senior physicist was response for the QA of two accelerators due to the limited physicists. The daily QA was carried out by the physicists and therapists in the morning

and the monthly QA and annual QA were performed at weekends. The results of daily

monthly and annual QAs were filled in the electronic form. Results: The standardized QA protocols were established and strictly followed. The QA results of radiotherapy were digitized

which directly showed the accelerator QA status. Conclusion: The standardized radiotherapy QA protocols should be established and implemented

and it is worth spreading widely in clinics.

关键词

Keywords

references

Views

3219

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Treatment strategies and prognostic analysis of 87 patients with salivary duct carcinoma: a retrospective cohort study

Advancements in the research of immunomodulatory effects of radiation therapy: from basic to clinical

Value of global longitudinal strain in assessing radiation-induced heart disease in breast cancer: systematic review and meta-analysis

The current data and challenge of radiotherapy in the case management of gastric cancer

Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects

Related Author

Peiguo WANG

Ximei ZHANG

Yixuan ZHOU

Yan ZHAO

Xuan ZHOU

Xudong WANG

Yingbin YAN

Nan BI

Related Institution

Department of Maxillofacial Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Malignant Tumors

Tianjin Key Laboratory of Oral and Maxillofacial Functional Reconstruction

Department of Oral and Maxillofacial-Head and Neck Surgery, Tianjin Stomatological Hospital Affiliated to Nankai University School of Medicine

Stomatological Clinical College of Tianjin Medical University

Tianjin Clinical Research Center for Malignant Tumors

AI问答

⁰